Literature DB >> 18307376

Diagnosing attention-deficit/hyperactivity disorder in patients with substance use disorders.

Frances Rudnick Levin1.   

Abstract

Diagnosing attention-deficit/hyperactivity disorder (ADHD) in adults can be complicated by several factors including the inability to meet appropriate developmental criteria as listed in the DSM-IV. The stringent DSM-IV criteria for ADHD may make diagnosing ADHD in adults difficult, which may lead to an underdiagnosis of ADHD in the adult population. Clinicians must rely on the diagnosis of ADHD not otherwise specified for adults with ADHD symptomatology, but this category does not provide clear delineations for patients whose symptoms vary within this category. Further complications arise due to high rates of comorbid psychiatric disorders, especially substance use disorders, in individuals with ADHD. Comorbid substance use disorders in individuals with ADHD can have a negative impact on the course of illness and quality of life. Further, cognitive deficits associated with substance abuse can hinder the ability to recall ADHD symptoms for appropriate diagnostic purposes. On the other hand, symptoms associated with intoxication or withdrawal may mimic ADHD symptoms, which can lead to an overdiagnosis of ADHD in the substance use disorder population. Another factor that can lead to the overdiagnosis of ADHD in the substance use disorder population is that patients may feign ADHD symptoms in order to obtain stimulant medication. If proper attention is paid to age-appropriate symptoms of ADHD, and careful longitudinal data are obtained from patients presenting with ADHD or substance use disorders, proper treatment can be given to patients with these comorbid disorders.

Entities:  

Mesh:

Year:  2007        PMID: 18307376

Source DB:  PubMed          Journal:  J Clin Psychiatry        ISSN: 0160-6689            Impact factor:   4.384


  7 in total

Review 1.  An update on the pharmacotherapy of attention-deficit/hyperactivity disorder in adults.

Authors:  Timothy E Wilens; Nicholas R Morrison; Jefferson Prince
Journal:  Expert Rev Neurother       Date:  2011-10       Impact factor: 4.618

Review 2.  Pharmacological and clinical dilemmas of prescribing in co-morbid adult attention-deficit/hyperactivity disorder and addiction.

Authors:  José Pérez de los Cobos; Núria Siñol; Víctor Pérez; Joan Trujols
Journal:  Br J Clin Pharmacol       Date:  2014-02       Impact factor: 4.335

3.  The utility of attention-deficit/hyperactivity disorder screening instruments in individuals seeking treatment for substance use disorders.

Authors:  Elias Dakwar; Amy Mahony; Martina Pavlicova; Andrew Glass; Daniel Brooks; John J Mariani; John Grabowski; Frances Rudnick Levin
Journal:  J Clin Psychiatry       Date:  2012-11       Impact factor: 4.384

4.  ADHD Is Highly Prevalent in Patients Seeking Treatment for Cannabis Use Disorders.

Authors:  Daniel P Notzon; Martina Pavlicova; Andrew Glass; John J Mariani; Amy L Mahony; Daniel J Brooks; Frances R Levin
Journal:  J Atten Disord       Date:  2016-03-31       Impact factor: 3.256

Review 5.  Ethylphenidate as a selective dopaminergic agonist and methylphenidate-ethanol transesterification biomarker.

Authors:  Kennerly S Patrick; Timothy R Corbin; Cristina E Murphy
Journal:  J Pharm Sci       Date:  2014-10-09       Impact factor: 3.534

6.  Adult attention-deficit hyperactivity disorders and its correlates in patients with opioid dependence: An exploratory study.

Authors:  Snehil Gupta; Gayatri Bhatia; Siddharth Sarkar; Biswadip Chatterjee; Yatan Pal Singh Balhara; Anju Dhawan
Journal:  Indian J Psychiatry       Date:  2020-10-10       Impact factor: 1.759

7.  Memory function in opioid-dependent patients treated with methadone or buprenorphine along with benzodiazepine: longitudinal change in comparison to healthy individuals.

Authors:  Pekka Rapeli; Carola Fabritius; Hely Kalska; Hannu Alho
Journal:  Subst Abuse Treat Prev Policy       Date:  2009-04-17
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.